Local Manufacturing and Establishment Registration in Nigeria

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

For locally manufactured and imported devices, the registration process in Nigeria is largely identical, but the sample route differs:

  • Imported devices: the applicant submits samples to VBM-R&RA itself (VBM-R&RA-GDL-001-01 §8.1);
  • Locally manufactured devices: samples are drawn by DER (the Directorate of Drug Evaluation and Research) (§8.2).

The 2025 draft adds §46 Registration of Establishment within the registration Part — treating the establishment itself as an independent registration object. The draft is not gazetted, but the direction is clear: Nigeria is splitting product registration and establishment registration into two separate tracks. Companies watching only the product rules should therefore also watch the establishment rules, because the second track may determine when the first one can even begin.

2. Legal basis

InstrumentReference numberDateProvisions
NAFDAC Guidelines for Registration of Medical Devices Including In Vitro Diagnostics (IVDs) and Related ProductsVBM-R&RA-GDL-001-01Effective 10 April 2025§8.1 (imported devices, applicant submits samples), §8.2 (locally manufactured, sampled by DER)
NAFDAC Guidelines for Registration of Medical Devices (Imported and Locally Manufactured) in NigeriaR&R-GDL-008-02Effective 3 May 2024§5.0–§5.1 (GMP steps), §7.0–§7.1.4 (laboratory analysis)
NAFDAC Medical Devices GMP Guidelines 2024DER-GDL-025-00Effective 11 November 2024Entire document (quality system requirements for local manufacturing)
NAFDAC Medical Devices, including In-vitro Diagnostics and Related Products Regulations, 2025 (draft)None (draft, not gazetted)Published 23 July 2025§46 (registration of establishment), §17–§31 (manufacturing, draft)

3. Expert insights

Insight 1: the fork in the sample route is who carries the samples to the laboratory.

For imported devices the applicant delivers the samples to VBM-R&RA; for locally manufactured devices the samples are drawn by DER. This looks like a procedural detail, but it determines who controls the schedule: for imported devices the company can arrange the sample submission date autonomously; for local manufacturing the sampling must be coordinated with DER, and the company is the passive party. Any slippage in that coordination pushes the laboratory stage, and with it the entire review timeline, to the right.

Insight 2: GMP review of local manufacturing is physically reachable, which brings both risk and opportunity.

R&R-GDL-008-02 §5.0–§5.1 places GMP as the first step of the registration process. For local manufacturing this means NAFDAC can inspect on site — foreign inspections of overseas manufacturers are often hard to arrange, but a local factory will certainly be inspected. This is a compliance pressure, but also a responsiveness advantage relative to imported products: a local holder can react to queries, sample failures and inspection findings without waiting on international logistics.

Insight 3: if §46 establishment registration is gazetted, it will change the compliance structure of one factory, many products.

Product registration issues certificates product by product; establishment registration would certify the establishment itself. If §46 lands, a local factory would need establishment registration before product registration can proceed — a two-certificate structure similar to a manufacturing licence plus product registration. For companies planning a Nigerian plant this is a major preliminary item. The sequencing requirement would affect factory investment timing, product launch plans and the contractual split between the manufacturing entity and the registration holder.

Insight 4: the draft manufacturing Part (§17–§31) and establishment registration are one package.

§46 does not stand alone; it closes the loop with Part 3’s §18 quality system, §22 design controls, §23 validation and verification, §27 QA/QC, §30 quality audits, §31 handling of non-compliance with GMP. At the current layer, build the system on DER-GDL-025-00 first, and it will connect naturally once the draft is gazetted.

Insight 5: locally manufactured IVDs need special attention to local verification of analytical performance.

Chapter 3 of VBM-R&RA-GDL-005-01 requires analytical performance and other evidence, and the studies must include actual results rather than only pass/fail outcomes, the number of invalid tests, photographs and copies of third-party contracts. For locally manufactured IVDs, performance data under the local population and local climate conditions are a review focus, and at the same time an advantage relative to imported products. Evidence generated in the country where the product will actually be used answers the applicability questions that imported dossiers struggle with.

4. Practical recommendations

  1. Coordinate the DER sampling date early for local manufacturing projects, and put the sampling milestone into the project schedule.
  2. Build the QMS on DER-GDL-025-00 first, and pre-fill elements such as design controls and quality audits against draft §17–§31.
  3. Companies planning a plant should list §46 establishment registration as a preliminary item, assessed at the investment decision stage.
  4. Locally manufactured IVDs should prepare analytical performance data for the local population and climate conditions.
  5. Prepare sample-accompanying documents per §7.0–§7.1.4: application letter, payment evidence, CoA, submission receipts.
  6. Track the gazettal progress of §46, and assess transitional arrangements for existing establishments as soon as it is gazetted.

5. Verification checklist

  • □ The sample route has been confirmed: imported — applicant submits; locally manufactured — DER samples (§8.1–§8.2).
  • □ The DER sampling date has been coordinated and entered into the schedule.
  • □ The QMS has been established on DER-GDL-025-00 and pre-filled against draft §17–§31.
  • □ §46 establishment registration has been listed as a preliminary assessment item for plant projects (draft).
  • □ Local performance data for locally manufactured IVDs has been prepared.
  • □ Sample-accompanying documents have been assembled per §7.0–§7.1.4.
  • □ A §46 gazettal tracking mechanism is in place.

Regulatory information verified as of 29 October 2026. All content cited in this document has been checked against the official NAFDAC guidelines (VBM-R&RA-GDL-001-01 §8.1–§8.2, effective 10 April 2025; R&R-GDL-008-02 §5.0–§5.1 and §7.0–§7.1.4, effective 3 May 2024; VBM-R&RA-GDL-005-01 Chapter 3, effective 17 March 2025) and the GMP guidelines (DER-GDL-025-00, effective 11 November 2024); the 2025 draft §46 and §17–§31 were published on 23 July 2025 and are not yet gazetted, and are provided for regulatory direction only.

  • Local Nigeria resources: GRZAN can coordinate locally licensed import entities and authorized representative resources, covering NAPAMS online submission, dossier screening clearance interfacing, import permits, sample delivery and laboratory analysis support.
  • Service capability: classification determination, registration pathway selection, technical documentation (IMDRF ToC) drafting, CMFS and notarization/legalization, GMP and foreign inspection preparation, advertisement permits, vigilance and PMS reporting, change management and renewal.
  • Contact: info@grzanglobal.com; website www.grzan.cn.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail